Orna Therapeutics, Vertex Pharma Enter Three-year Research Collaboration - Quick Facts
Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...
FierceBiotech1h
Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
Bernstein Remains a Hold on Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by CWA Asset Management Group LLC
CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...
Nordea Investment Management AB Purchases 55,739 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...
Zacks.com on MSN13h
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
The stock's fall snapped a three-day winning streak.
BioSpace23h
5 FDA Decisions to Watch in Q1
Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...